HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer

NCT05728619 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Extensive Stage Small Cell Lung Carcinoma

Interventions

DRUG: HTMC0435
DRUG: Temozolomide

Sponsor

Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.